MMMalika Mellaoui

Malika Mellaoui

*This is an algorithmically generated author record based on publicly available information.

Malika Mellaoui has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Design and simulation of a high gain efficient frequency reconfigurable miniaturized micro strip antenna for millimeter-wave application with enhancing gain and efficiency using the PIN diode

    by Tibermacine Badreddine, Hamaizia Zohra, Guesbaya Tahar, Mellaoui Malika, Madani Lotfi

    Due to congestion and deterioration in the electromagnetic spectrum below 10 GHz. Research is being done on the migration to the millimeter-wave spectrum. In this paper, a novel compact (6.4 x 7 x 0.8) mm3 frequency reconfigurable microstrip patch antenna is introduced, which operates at V, Q, and E-Bands. A P-I-N diode positioned between the primary patch and the secondary patch controls the frequency re-configurability and the antenna's gain and efficiency improvement. The patches are made of copper material printed on a Rogers RT5880LZ with a thickness, relative permittivity, and loss tang of 0.8 mm, 2.2, and 0.0009. An optimum gain and efficiency have been obtained at 52.4 GHz, 9 dB and 95.5 percent, and with a little less 8.64 dB and 95 percent, with a low side lobe level (SLL) of -19.8 dB at 57.8 GHz and a broad bandwidth of 4.6 GHz at 83 GHz, respectively. The antenna is designed using CST Studio software.

  • Open Access

    Potential novel HIV-1 reverse transcriptase inhibitors: a modeling and evaluation approach

    by Malika Mellaoui, Radhia Mazri, Mohamed Mouadh Messaoui, Aicha Kerassa, Mebarka Ouassaf

    Human immunodeficiency viru (HIV) is the causative agent of acquired immunodeficiency syndrome (AIDS), a disease that severely weakens the immune system and makes patients more susceptible to infections. Although there is no definitive cure for HIV, advances in drug development offer promising prospects. In this study, we targeted HIV-1 reverse transcriptase by performing virtual screening (VS) to identify novel candidate compounds. From a database of compounds similar to the inhibitor thymidine-5'-triphosphate (TTP), three compounds (CID441663, CID123650073, and CID123789980) were selected for their docking scores, which outperformed those of the reference compound TTP (-6.2302 kcal/mol). These compounds were then subjected to ADMET, PASS, and DFT analyses. Interestingly, all three ligands showed a broad spectrum of predicted antiviral activity, including targets related to human herpes virus and HIV. Specifically, while TTP primarily targets HIV-1 reverse transcriptase, the top three ligands were predicted to target HIV-1 integrase, with CID441663 and CID123789980 displaying higher confidence in this target compared to CID123650073. These findings suggest that the candidate ligands should undergo further in vitro validation to determine their precise roles as inhibitors or antagonists, and to confirm their selective targeting of HIV-related proteins.